Protein Therapeutic for Erectile Dysfunction

Case ID:
Disclosure Date:
UNMET NEED: Erectile dysfunction (ED) affects around 52% of U.S. men due to a wide variety of causes. Standard treatment for ED patients comprises of PDE5 inhibitors (e.g., Viagra) administration, which restores function for only 40% of all patients. As such, there is a significant need for preventing and treating erectile dysfunction of any etiology including post-surgery, diabetes, cardiovascular disease, and other metabolic disturbances.
TECHNICAL OVERVIEW: The disclosed invention employs an injected, naturally-produced biological molecule to initiate stem cell recruitment and allow nerve regeneration in the area of dysfunction. This cures the root cause of erectile dysfunction in patients, rather than provide short-term relief with drugs currently on the market to treat ED. The disclosed invention not only treats ED resulting from prostatectomies, but also ED caused by age, diabetes, cardiovascular disease, and other metabolic disturbances.
STAGE OF DEVELOPMENT: Animal model data available.
ASSOCIATED INVENTORS: Trinity Bivalacqua, Nikolai Sopko, Marc Penn
PATENT STATUS: Pending Provisional Application
Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
Stromal Derived Factor-1 Treatment and Prevention of Erectile Dysfunction PRO: Provisional United States 62/505,864 5/13/2017     Pending
For Information, Contact:
Vera Sampels
Save This Technology:
2017 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum